NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|6324283|ref|NP_014353|]
View 

bifunctional aminopeptidase/epoxide hydrolase [Saccharomyces cerevisiae S288C]

Protein Classification

M1 family metallopeptidase( domain architecture ID 11494248)

M1 family metallopeptidase such as aminopeptidase N, a broad specificity aminopeptidase, and glutamyl aminopeptidase, which releases N-terminal glutamate from a peptide

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
57-669 0e+00

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


:

Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 1064.78  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283     57 DQSTLSNYKDFAVLHTDLNLSVSFEKSAISGSVTFQLKKLHEGKNKsdeLHLDTSYLDVQEVHIDGSKADFQIEQRKEPL 136
Cdd:TIGR02411   1 DPSSLSNYKDFRTSHTDLNLSVDFTKRKLSGSVTFTLKSLTDNLNK---LVLDTSYLDIQKVTINGLPADFAIGERKEPL 77
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    137 GSRLVINNA---SCNDNFTLNIQFRTTDKCTALQWLNSKQTKGGK-PYVFSQLEAIHARSLFPCFDTPSVKSTFTASIES 212
Cdd:TIGR02411  78 GSPLTISLPiatSKNDEFVLNISFSTTPKCTALQWLNPEQTSGKKhPYLFSQCQAIHARSLFPCQDTPSVKSTYTAEVES 157
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    213 PLPVVFSGIRIEDTSKDTNIYRFEQKVPIPAYLIGIASGDLSSAPIGPRSTVYTEPFRLKDCQWEFENDVEKFIQTAEKI 292
Cdd:TIGR02411 158 PLPVLMSGIRDGETSNDPGKYLFKQKVPIPAYLIAIASGDLASAPIGPRSTVYSEPEQLEKCQYEFENDTEKFIKTAEDL 237
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    293 IFEYEWGTYDILVNVDSYPYGGMESPNMTFATPTLIAHDRSNIDVIAHELAHSWSGNLVTNCSWNHFWLNEGWTVYLERR 372
Cdd:TIGR02411 238 IFPYEWGQYDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNCSWEHFWLNEGWTVYLERR 317
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    373 IIGAIHGEPTRHFSALIGWSDLQNSIDSMKDPERFSTLVQNLNDNtDPDDAFSTVPYEKGFNLLFHLETILGGKAEFDPF 452
Cdd:TIGR02411 318 IIGRLYGEKTRHFSALIGWGDLQESVKTLGETPEFTKLVVDLKDN-DPDDAFSSVPYEKGFNFLFYLEQLLGGPAEFDPF 396
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    453 IRHYFKKFAKKSLDTFQFLDTLYEFYPEKKEI--LDSVDWETWLYKPGMPP-RPHFITALADNVYQLADKWVEMAQHlkt 529
Cdd:TIGR02411 397 LRHYFKKFAYKSLDTYQFKDALYEYFKDKKKVdkLDAVDWETWLYSPGMPPvKPNFDTTLADECYALADRWVDAAKA--- 473
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    530 teDFRSEFNAIDIKDFNSNQLVLFLETLTQNGHsnkkpkdfDWAKFPVASRALLDIYqdNIVKSQNAEVVFKMFKFQIFA 609
Cdd:TIGR02411 474 --DDLSSFNAKDIKDFSSHQLVLFLETLTERGG--------DWALPEGHIKRLGDIY--NFAASKNAEVRFRWFRLAIQA 541
                         570       580       590       600       610       620
                  ....*....|....*....|....*....|....*....|....*....|....*....|.
gi 6324283    610 KLQEEYKHLADWLGTVGRMKFVRPGYRLLNS-VDRRLALATFDKFKDTYHPICKALVKQDL 669
Cdd:TIGR02411 542 KLEDEYPLLADWLGTVGRMKFVRPGYRLLNAfVDRDLAIRTFEKFKDSYHPICAMLVKKDL 602
 
Name Accession Description Interval E-value
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
57-669 0e+00

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 1064.78  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283     57 DQSTLSNYKDFAVLHTDLNLSVSFEKSAISGSVTFQLKKLHEGKNKsdeLHLDTSYLDVQEVHIDGSKADFQIEQRKEPL 136
Cdd:TIGR02411   1 DPSSLSNYKDFRTSHTDLNLSVDFTKRKLSGSVTFTLKSLTDNLNK---LVLDTSYLDIQKVTINGLPADFAIGERKEPL 77
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    137 GSRLVINNA---SCNDNFTLNIQFRTTDKCTALQWLNSKQTKGGK-PYVFSQLEAIHARSLFPCFDTPSVKSTFTASIES 212
Cdd:TIGR02411  78 GSPLTISLPiatSKNDEFVLNISFSTTPKCTALQWLNPEQTSGKKhPYLFSQCQAIHARSLFPCQDTPSVKSTYTAEVES 157
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    213 PLPVVFSGIRIEDTSKDTNIYRFEQKVPIPAYLIGIASGDLSSAPIGPRSTVYTEPFRLKDCQWEFENDVEKFIQTAEKI 292
Cdd:TIGR02411 158 PLPVLMSGIRDGETSNDPGKYLFKQKVPIPAYLIAIASGDLASAPIGPRSTVYSEPEQLEKCQYEFENDTEKFIKTAEDL 237
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    293 IFEYEWGTYDILVNVDSYPYGGMESPNMTFATPTLIAHDRSNIDVIAHELAHSWSGNLVTNCSWNHFWLNEGWTVYLERR 372
Cdd:TIGR02411 238 IFPYEWGQYDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNCSWEHFWLNEGWTVYLERR 317
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    373 IIGAIHGEPTRHFSALIGWSDLQNSIDSMKDPERFSTLVQNLNDNtDPDDAFSTVPYEKGFNLLFHLETILGGKAEFDPF 452
Cdd:TIGR02411 318 IIGRLYGEKTRHFSALIGWGDLQESVKTLGETPEFTKLVVDLKDN-DPDDAFSSVPYEKGFNFLFYLEQLLGGPAEFDPF 396
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    453 IRHYFKKFAKKSLDTFQFLDTLYEFYPEKKEI--LDSVDWETWLYKPGMPP-RPHFITALADNVYQLADKWVEMAQHlkt 529
Cdd:TIGR02411 397 LRHYFKKFAYKSLDTYQFKDALYEYFKDKKKVdkLDAVDWETWLYSPGMPPvKPNFDTTLADECYALADRWVDAAKA--- 473
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    530 teDFRSEFNAIDIKDFNSNQLVLFLETLTQNGHsnkkpkdfDWAKFPVASRALLDIYqdNIVKSQNAEVVFKMFKFQIFA 609
Cdd:TIGR02411 474 --DDLSSFNAKDIKDFSSHQLVLFLETLTERGG--------DWALPEGHIKRLGDIY--NFAASKNAEVRFRWFRLAIQA 541
                         570       580       590       600       610       620
                  ....*....|....*....|....*....|....*....|....*....|....*....|.
gi 6324283    610 KLQEEYKHLADWLGTVGRMKFVRPGYRLLNS-VDRRLALATFDKFKDTYHPICKALVKQDL 669
Cdd:TIGR02411 542 KLEDEYPLLADWLGTVGRMKFVRPGYRLLNAfVDRDLAIRTFEKFKDSYHPICAMLVKKDL 602
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
57-495 0e+00

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 713.85  E-value: 0e+00
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283   57 DQSTLSNYKDFAVLHTDLNLSVSFEKSAISGSVTFQLKKLhegKNKSDELHLDTSYLDVQEVHIDGSK-ADFQIEQRKEP 135
Cdd:cd09599   1 DPSSFSNYDEVRTTHLDLDLTVDFDKKTISGSATLTLEVL---QDGADELVLDTRDLDISSVTVNGGKeLKFELGPRDPV 77
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  136 LGSRLVIN---NASCNDNFTLNIQFRTTDKCTALQWLNSKQTKGGK-PYVFSQLEAIHARSLFPCFDTPSVKSTFTASIE 211
Cdd:cd09599  78 LGSALTITlpsPLAKGDTFKVKIEYSTTPQATALQWLTPEQTAGKKhPYLFTQCQAIHARSLFPCQDTPSVKSTYSATVT 157
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  212 SP--LPVVFSGIRIEDTSK-DTNIYRFEQKVPIPAYLIGIASGDLSSAPIGPRSTVYTEPFRLKDCQWEFEnDVEKFIQT 288
Cdd:cd09599 158 VPkgLTALMSALRTGEKEEaGTGTYTFEQPVPIPSYLIAIAVGDLESREIGPRSGVWAEPSVVDAAAEEFA-DTEKFLKA 236
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  289 AEKIIFEYEWGTYDILVNVDSYPYGGMESPNMTFATPTLIAHDRSNIDVIAHELAHSWSGNLVTNCSWNHFWLNEGWTVY 368
Cdd:cd09599 237 AEKLYGPYVWGRYDLLVLPPSFPYGGMENPCLTFATPTLIAGDRSLVDVIAHEIAHSWSGNLVTNANWEHFWLNEGFTVY 316
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  369 LERRIIGAIHGEPTRHFSALIGWSDLQNSIDSMKDPERFSTLVQNLnDNTDPDDAFSTVPYEKGFNLLFHLETiLGGKAE 448
Cdd:cd09599 317 LERRILERLYGEEYRQFEAILGWKDLQESIKEFGEDPPYTLLVPDL-KGVDPDDAFSSVPYEKGFQFLYYLEQ-LGGREV 394
                       410       420       430       440
                ....*....|....*....|....*....|....*....|....*...
gi 6324283  449 FDPFIRHYFKKFAKKSLDTFQFLDTLYEFYPEKK-EILDSVDWETWLY 495
Cdd:cd09599 395 FDPFLRAYFKKFAFQSIDTEDFKDFLLEYFAEDKpEILDKIDWDAWLY 442
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
48-500 6.93e-83

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 273.44  E-value: 6.93e-83
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283   48 RRPSRSPEYDQStlsnykDFAVLHTDLNLSVSFEKSAISGSVTFQLKKLhegKNKSDELHLDTSYLDVQEVHIDGSKADF 127
Cdd:COG0308   2 KRLTRLEAYRPP------GYDVTHYDLDLDLDPATTRLSGTATITFTAT---EAPLDSLVLDLKGLEVTSVTVDGKPLDF 72
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  128 QIEqrkeplGSRLVINNASC---NDNFTLNIQFRTTDKCTALQWLNSKQTKGGKPYVFSQLEAIHARSLFPCFDTPSVKS 204
Cdd:COG0308  73 TRD------GERLTITLPKPlapGETFTLEIEYSGKPSNGGEGLYRSGDPPDGPPYLYTQCEPEGARRWFPCFDHPDDKA 146
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  205 TFTASIESPL-PVVFS-GIRIEDTSKD--TNIYRFEQKVPIPAYLIGIASGDL----SSAPIGPRSTVYTEPFRLKDCQW 276
Cdd:COG0308 147 TFTLTVTVPAgWVAVSnGNLVSETELGdgRTTWHWADTQPIPTYLFALAAGDYavveDTFASGVPLRVYVRPGLADKAKE 226
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  277 EFEnDVEKFIQTAEKII-FEYEWGTYDILVnVDSYPYGGMESPNMTFATPTLIAHDRSNID-------VIAHELAHSWSG 348
Cdd:COG0308 227 AFE-STKRMLDFFEELFgVPYPFDKYDQVA-VPDFNFGAMENQGLVTFGEKVLADETATDAdyerresVIAHELAHQWFG 304
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  349 NLVTNCSWNHFWLNEGWTVYLERRIIGAIHGEPTRHFSALIGWSDLQNSIDSmkdpeRFSTLVQNLNDNTDPDDAFSTVP 428
Cdd:COG0308 305 NLVTCADWDDLWLNEGFATYMEQLFSEDLYGKDAADRIFVGALRSYAFAEDA-----GPNAHPIRPDDYPEIENFFDGIV 379
                       410       420       430       440       450       460       470
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|..
gi 6324283  429 YEKGFNLLFHLETILgGKAEFDPFIRHYFKKFAKKSLDTFQFLDTLYEFYPEKkeiLDSVdWETWLYKPGMP 500
Cdd:COG0308 380 YEKGALVLHMLRTLL-GDEAFRAGLRLYFARHAGGNATTEDFLAALEEASGRD---LSAF-FDQWLYQAGLP 446
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
276-493 2.75e-71

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 230.25  E-value: 2.75e-71
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    276 WEFENDVEKFIQTAEKIIFEYEWGTYDILVnVDSYPYGGMESPNMTFATPTLIAHD---------RSNIDVIAHELAHSW 346
Cdd:pfam01433   1 YALEITVKLLEFYEDYFNIPYPLPKYDLVA-LPDFSAGAMENWGLITYRETLLLYDpgnsstsdkQRVASVIAHELAHQW 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    347 SGNLVTNCSWNHFWLNEGWTVYLERRIIGAIhgEPTRHFSALIGWSDLQN--SIDSMKDPERFStlvQNLNDNTDPDDAF 424
Cdd:pfam01433  80 FGNLVTMKWWDDLWLNEGFATYMEYLGTDAL--FPEWNIWEQFLLDEVQNamARDALDSSHPIT---QNVNDPSEIDDIF 154
                         170       180       190       200       210       220
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....
gi 6324283    425 STVPYEKGFNLLFHLETILgGKAEFDPFIRHYFKKFAKKSLDTFQFLDTLYEFYpeKKEILDSVdWETW 493
Cdd:pfam01433 155 DAIPYEKGASVLRMLETLL-GEEVFQKGLRSYLKKFQYGNATTEDLWDALSEAS--GPLDVDSF-MDTW 219
 
Name Accession Description Interval E-value
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
57-669 0e+00

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 1064.78  E-value: 0e+00
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283     57 DQSTLSNYKDFAVLHTDLNLSVSFEKSAISGSVTFQLKKLHEGKNKsdeLHLDTSYLDVQEVHIDGSKADFQIEQRKEPL 136
Cdd:TIGR02411   1 DPSSLSNYKDFRTSHTDLNLSVDFTKRKLSGSVTFTLKSLTDNLNK---LVLDTSYLDIQKVTINGLPADFAIGERKEPL 77
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    137 GSRLVINNA---SCNDNFTLNIQFRTTDKCTALQWLNSKQTKGGK-PYVFSQLEAIHARSLFPCFDTPSVKSTFTASIES 212
Cdd:TIGR02411  78 GSPLTISLPiatSKNDEFVLNISFSTTPKCTALQWLNPEQTSGKKhPYLFSQCQAIHARSLFPCQDTPSVKSTYTAEVES 157
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    213 PLPVVFSGIRIEDTSKDTNIYRFEQKVPIPAYLIGIASGDLSSAPIGPRSTVYTEPFRLKDCQWEFENDVEKFIQTAEKI 292
Cdd:TIGR02411 158 PLPVLMSGIRDGETSNDPGKYLFKQKVPIPAYLIAIASGDLASAPIGPRSTVYSEPEQLEKCQYEFENDTEKFIKTAEDL 237
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    293 IFEYEWGTYDILVNVDSYPYGGMESPNMTFATPTLIAHDRSNIDVIAHELAHSWSGNLVTNCSWNHFWLNEGWTVYLERR 372
Cdd:TIGR02411 238 IFPYEWGQYDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNCSWEHFWLNEGWTVYLERR 317
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    373 IIGAIHGEPTRHFSALIGWSDLQNSIDSMKDPERFSTLVQNLNDNtDPDDAFSTVPYEKGFNLLFHLETILGGKAEFDPF 452
Cdd:TIGR02411 318 IIGRLYGEKTRHFSALIGWGDLQESVKTLGETPEFTKLVVDLKDN-DPDDAFSSVPYEKGFNFLFYLEQLLGGPAEFDPF 396
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    453 IRHYFKKFAKKSLDTFQFLDTLYEFYPEKKEI--LDSVDWETWLYKPGMPP-RPHFITALADNVYQLADKWVEMAQHlkt 529
Cdd:TIGR02411 397 LRHYFKKFAYKSLDTYQFKDALYEYFKDKKKVdkLDAVDWETWLYSPGMPPvKPNFDTTLADECYALADRWVDAAKA--- 473
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    530 teDFRSEFNAIDIKDFNSNQLVLFLETLTQNGHsnkkpkdfDWAKFPVASRALLDIYqdNIVKSQNAEVVFKMFKFQIFA 609
Cdd:TIGR02411 474 --DDLSSFNAKDIKDFSSHQLVLFLETLTERGG--------DWALPEGHIKRLGDIY--NFAASKNAEVRFRWFRLAIQA 541
                         570       580       590       600       610       620
                  ....*....|....*....|....*....|....*....|....*....|....*....|.
gi 6324283    610 KLQEEYKHLADWLGTVGRMKFVRPGYRLLNS-VDRRLALATFDKFKDTYHPICKALVKQDL 669
Cdd:TIGR02411 542 KLEDEYPLLADWLGTVGRMKFVRPGYRLLNAfVDRDLAIRTFEKFKDSYHPICAMLVKKDL 602
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
57-495 0e+00

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 713.85  E-value: 0e+00
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283   57 DQSTLSNYKDFAVLHTDLNLSVSFEKSAISGSVTFQLKKLhegKNKSDELHLDTSYLDVQEVHIDGSK-ADFQIEQRKEP 135
Cdd:cd09599   1 DPSSFSNYDEVRTTHLDLDLTVDFDKKTISGSATLTLEVL---QDGADELVLDTRDLDISSVTVNGGKeLKFELGPRDPV 77
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  136 LGSRLVIN---NASCNDNFTLNIQFRTTDKCTALQWLNSKQTKGGK-PYVFSQLEAIHARSLFPCFDTPSVKSTFTASIE 211
Cdd:cd09599  78 LGSALTITlpsPLAKGDTFKVKIEYSTTPQATALQWLTPEQTAGKKhPYLFTQCQAIHARSLFPCQDTPSVKSTYSATVT 157
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  212 SP--LPVVFSGIRIEDTSK-DTNIYRFEQKVPIPAYLIGIASGDLSSAPIGPRSTVYTEPFRLKDCQWEFEnDVEKFIQT 288
Cdd:cd09599 158 VPkgLTALMSALRTGEKEEaGTGTYTFEQPVPIPSYLIAIAVGDLESREIGPRSGVWAEPSVVDAAAEEFA-DTEKFLKA 236
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  289 AEKIIFEYEWGTYDILVNVDSYPYGGMESPNMTFATPTLIAHDRSNIDVIAHELAHSWSGNLVTNCSWNHFWLNEGWTVY 368
Cdd:cd09599 237 AEKLYGPYVWGRYDLLVLPPSFPYGGMENPCLTFATPTLIAGDRSLVDVIAHEIAHSWSGNLVTNANWEHFWLNEGFTVY 316
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  369 LERRIIGAIHGEPTRHFSALIGWSDLQNSIDSMKDPERFSTLVQNLnDNTDPDDAFSTVPYEKGFNLLFHLETiLGGKAE 448
Cdd:cd09599 317 LERRILERLYGEEYRQFEAILGWKDLQESIKEFGEDPPYTLLVPDL-KGVDPDDAFSSVPYEKGFQFLYYLEQ-LGGREV 394
                       410       420       430       440
                ....*....|....*....|....*....|....*....|....*...
gi 6324283  449 FDPFIRHYFKKFAKKSLDTFQFLDTLYEFYPEKK-EILDSVDWETWLY 495
Cdd:cd09599 395 FDPFLRAYFKKFAFQSIDTEDFKDFLLEYFAEDKpEILDKIDWDAWLY 442
M1 cd09595
Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 ...
71-476 1.22e-86

Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 hydrolase; The model represents the catalytic domains of M1 peptidase family members including aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). All peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile upon activation during catalysis. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. APN expression is dysregulated in many inflammatory diseases and is enhanced in numerous tumor cells, making it a lead target in the development of anti-cancer and anti-inflammatory drugs. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase in LTA4H is as yet unknown, while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals.


Pssm-ID: 341058 [Multi-domain]  Cd Length: 413  Bit Score: 277.40  E-value: 1.22e-86
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283   71 HTDLNLSVSFEKSAISGSVTFQLKklhEGKNKSDeLHLDTSYLDVQEVHIDGSKADFQIEQRkePLGSRLVINNASCNDN 150
Cdd:cd09595   2 HYDLDLDVDFTTKTLNGTETLTVD---ASQVGRE-LVLDLVGLTIHSVSVNGAAVDFGEREH--YDGEKLTIPGPKPPGQ 75
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  151 -FTLNIQFRTTDKCTALQWLNSKQTKGGKPYVFSQLEAIHARSLFPCFDTPSVKSTFTASIESPLP--VVFSG--IRIED 225
Cdd:cd09595  76 tFTVRISFEAKPSKNLLGWLWEQTAGKEKPYLFTQFEATHARRIFPCIDHPAVKATFTVTITTPKKdlLASNGalVGEET 155
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  226 TSKDTNIYRFEQKVPIPAYLIGIASGDLSSAPIGPRST------VYTEPFRLKDCQWEFEnDVEKFIQTAEKII-FEYEW 298
Cdd:cd09595 156 GANGRKTYRFEDTPPIPTYLVAVVVGDLEFKYVTVKSQprvglsVYSEPLQVDQAQYAFD-ATRAALAWFEDYFgGPYPL 234
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  299 GTYDiLVNVDSYPYGGMESPNMTFATPTLIAHDRSNID-------VIAHELAHSWSGNLVTNCSWNHFWLNEGWTVYLER 371
Cdd:cd09595 235 PKYD-LLAVPDFNSGAMENPGLITFRTTYLLRSKVTDTgarsienVIAHELAHQWFGNLVTMRWWNDLWLNEGFAVYYEN 313
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  372 RIIGAIHGEPTRHFSALIGWSDLqNSIDSMKDPERFSTLVQNlndNTDPDDAFSTVPYEKGFNLLFHLETILGGKAeFDP 451
Cdd:cd09595 314 RIMDATFGTSSRHLDQLSGSSDL-NTEQLLEDSSPTSTPVRS---PADPDVAYDGVTYAKGALVLRMLEELVGEEA-FDK 388
                       410       420
                ....*....|....*....|....*
gi 6324283  452 FIRHYFKKFAKKSLDTFQFLDTLYE 476
Cdd:cd09595 389 GVQAYFNRHKFKNATTDDFIDALEE 413
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
48-500 6.93e-83

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 273.44  E-value: 6.93e-83
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283   48 RRPSRSPEYDQStlsnykDFAVLHTDLNLSVSFEKSAISGSVTFQLKKLhegKNKSDELHLDTSYLDVQEVHIDGSKADF 127
Cdd:COG0308   2 KRLTRLEAYRPP------GYDVTHYDLDLDLDPATTRLSGTATITFTAT---EAPLDSLVLDLKGLEVTSVTVDGKPLDF 72
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  128 QIEqrkeplGSRLVINNASC---NDNFTLNIQFRTTDKCTALQWLNSKQTKGGKPYVFSQLEAIHARSLFPCFDTPSVKS 204
Cdd:COG0308  73 TRD------GERLTITLPKPlapGETFTLEIEYSGKPSNGGEGLYRSGDPPDGPPYLYTQCEPEGARRWFPCFDHPDDKA 146
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  205 TFTASIESPL-PVVFS-GIRIEDTSKD--TNIYRFEQKVPIPAYLIGIASGDL----SSAPIGPRSTVYTEPFRLKDCQW 276
Cdd:COG0308 147 TFTLTVTVPAgWVAVSnGNLVSETELGdgRTTWHWADTQPIPTYLFALAAGDYavveDTFASGVPLRVYVRPGLADKAKE 226
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  277 EFEnDVEKFIQTAEKII-FEYEWGTYDILVnVDSYPYGGMESPNMTFATPTLIAHDRSNID-------VIAHELAHSWSG 348
Cdd:COG0308 227 AFE-STKRMLDFFEELFgVPYPFDKYDQVA-VPDFNFGAMENQGLVTFGEKVLADETATDAdyerresVIAHELAHQWFG 304
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  349 NLVTNCSWNHFWLNEGWTVYLERRIIGAIHGEPTRHFSALIGWSDLQNSIDSmkdpeRFSTLVQNLNDNTDPDDAFSTVP 428
Cdd:COG0308 305 NLVTCADWDDLWLNEGFATYMEQLFSEDLYGKDAADRIFVGALRSYAFAEDA-----GPNAHPIRPDDYPEIENFFDGIV 379
                       410       420       430       440       450       460       470
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|..
gi 6324283  429 YEKGFNLLFHLETILgGKAEFDPFIRHYFKKFAKKSLDTFQFLDTLYEFYPEKkeiLDSVdWETWLYKPGMP 500
Cdd:COG0308 380 YEKGALVLHMLRTLL-GDEAFRAGLRLYFARHAGGNATTEDFLAALEEASGRD---LSAF-FDQWLYQAGLP 446
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
276-493 2.75e-71

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 230.25  E-value: 2.75e-71
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    276 WEFENDVEKFIQTAEKIIFEYEWGTYDILVnVDSYPYGGMESPNMTFATPTLIAHD---------RSNIDVIAHELAHSW 346
Cdd:pfam01433   1 YALEITVKLLEFYEDYFNIPYPLPKYDLVA-LPDFSAGAMENWGLITYRETLLLYDpgnsstsdkQRVASVIAHELAHQW 79
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    347 SGNLVTNCSWNHFWLNEGWTVYLERRIIGAIhgEPTRHFSALIGWSDLQN--SIDSMKDPERFStlvQNLNDNTDPDDAF 424
Cdd:pfam01433  80 FGNLVTMKWWDDLWLNEGFATYMEYLGTDAL--FPEWNIWEQFLLDEVQNamARDALDSSHPIT---QNVNDPSEIDDIF 154
                         170       180       190       200       210       220
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....
gi 6324283    425 STVPYEKGFNLLFHLETILgGKAEFDPFIRHYFKKFAKKSLDTFQFLDTLYEFYpeKKEILDSVdWETW 493
Cdd:pfam01433 155 DAIPYEKGASVLRMLETLL-GEEVFQKGLRSYLKKFQYGNATTEDLWDALSEAS--GPLDVDSF-MDTW 219
M1_APN_like cd09603
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly ...
67-495 2.04e-57

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly bacterial and some archaeal M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341066 [Multi-domain]  Cd Length: 410  Bit Score: 199.73  E-value: 2.04e-57
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283   67 FAVLHTDLNLSVSFEKSAISGSVTFQLKKLHEgknkSDELHLDTSYLDVQEVHIDGSKADFQiEQRkeplGSRLVINNAS 146
Cdd:cd09603   1 YDVLHYDLDLDYDPATKSLSGTATITFRATQD----LDSLQLDLVGLTVSSVTVDGVPAAFF-THD----GDKLVITLPR 71
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  147 C---NDNFTLNIQFRTTDKCTALQWLNSKQTKGGKPYVFSQLEAIHARSLFPCFDTPSVKSTFTASI--ESPLPVVFSGI 221
Cdd:cd09603  72 PlaaGETFTVTVRYSGKPRPAGYPPGDGGGWEEGDDGVWTAGQPEGASTWFPCNDHPDDKATYDITVtvPAGLTVVSNGR 151
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  222 RIEDTSK--DTNIYRFEQKVPIPAYLIGIASGDLSSAPIGPRSTV----YTEPFRLKDCQWEFENdVEKFIQTAEKIIFE 295
Cdd:cd09603 152 LVSTTTNggGTTTWHWKMDYPIATYLVTLAVGRYAVVEDGSGGGIplryYVPPGDAAKAKASFAR-TPEMLDFFEELFGP 230
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  296 YEWGTYDILVnVDSYpYGGMESPNMTFATPTLIAHDRSNIDVIAHELAHSWSGNLVTNCSWNHFWLNEGWTVYLERRIIG 375
Cdd:cd09603 231 YPFEKYGQVV-VPDL-GGGMEHQTATTYGNNFLNGDRGSERLIAHELAHQWFGDSVTCADWADIWLNEGFATYAEWLWSE 308
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  376 AIHGEpTRHFSALIGW-SDLQNSIDSMKDPerfstlvqnlndnTDPDDAFSTVPYEKGFNLLFHLETILGGKAeFDPFIR 454
Cdd:cd09603 309 HKGGA-DAYRAYLAGQrQDYLNADPGPGRP-------------PDPDDLFDRDVYQKGALVLHMLRNLLGDEA-FFAALR 373
                       410       420       430       440
                ....*....|....*....|....*....|....*....|.
gi 6324283  455 HYFKKFAKKSLDTFQFLDTLYEFYPEKkeiLDSVdWETWLY 495
Cdd:cd09603 374 AYLARYAHGNVTTEDFIAAAEEVSGRD---LTWF-FDQWLY 410
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
70-487 2.54e-45

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 167.37  E-value: 2.54e-45
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283   70 LHTDLNLSVSFEKSAISGSVTFQLKKLHEgknkSDELHLDTSYLDVQEVHIDGSKADFQIEQRKEPLGSR--LVINNAS- 146
Cdd:cd09601   1 LHYDLTLTPDLENFTFSGSVTITLEVLEP----TDTIVLHAKDLTITSASLTLKGGSGIIEVTVVTDEETefLTITLDEt 76
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  147 --CNDNFTLNIQF--RTTDKCTALQWLNSKQTKGGKPYVFS-QLEAIHARSLFPCFDTPSVKSTFTASIESP--LPVVFS 219
Cdd:cd09601  77 lpPGENYTLSIEFtgKLNDDLRGFYRSSYTDEDGETRYLAAtQFEPTDARRAFPCFDEPAFKATFDITITHPkgYTALSN 156
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  220 GIRIEDTSKDTN--IYRFEQKVPIPAYLIGIASGDL----SSAPIGPRSTVYTEPFRLKDCQWEFEndvekfiqTAEKII 293
Cdd:cd09601 157 MPPVESTELEDGwkTTTFETTPPMSTYLVAFVVGDFeyieSTTKSGVPVRVYARPGKIEQGDFALE--------VAPKIL 228
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  294 FEYEwGTYDI--------LVNVDSYPYGGMEspN---MTFATPTLI-------AHDRSNI-DVIAHELAHSWSGNLVTNC 354
Cdd:cd09601 229 DFYE-DYFGIpyplpkldLVAIPDFAAGAME--NwglITYRETALLydpktssASDKQRVaEVIAHELAHQWFGNLVTMK 305
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  355 SWNHFWLNEGWTVYLERRIIGAIHgePTRHFSALIGWSDLQNS--IDSMKdperfST--LVQNLNDNTDPDDAFSTVPYE 430
Cdd:cd09601 306 WWDDLWLNEGFATYMEYLAVDKLF--PEWNMWDQFVVDELQSAleLDSLA-----SShpIEVPVESPSEISEIFDAISYS 378
                       410       420       430       440       450       460
                ....*....|....*....|....*....|....*....|....*....|....*....|..
gi 6324283  431 KGFNLLFHLETILGGKAeFDPFIRHYFKKFAKKSLDTFQFLDTLYEFYPEK-----KEILDS 487
Cdd:cd09601 379 KGASVLRMLENFLGEEV-FRKGLRKYLKKHAYGNATTDDLWEALQEASGESkpldvKEIMDS 439
Leuk-A4-hydro_C pfam09127
Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of ...
545-669 1.25e-44

Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of two layers of parallel alpha-helices, five in the inner layer and four in the outer, arranged in an antiparallel manner, with perpendicular loops containing short helical segments on top. They are required for the formation of a deep cleft harbouring the catalytic Zn2+ site in Leukotriene A4 hydrolase.


Pssm-ID: 462686  Cd Length: 112  Bit Score: 154.96  E-value: 1.25e-44
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    545 FNSNQLVLFLETLTQnghsnKKPKDfdwakfPVASRALLDIYqdNIVKSQNAEVVFKMFKFQIFAKLQEEYKHLADWLGT 624
Cdd:pfam09127   1 WSSNQKVVFLERLLE-----FSPLS------PEQLKALDEVY--KLSESKNAEIRFRWLRLALKAKYEPAYPEVAEFLGE 67
                          90       100       110       120
                  ....*....|....*....|....*....|....*....|....*
gi 6324283    625 VGRMKFVRPGYRLLNSVDRRLALATFDKFKDTYHPICKALVKQDL 669
Cdd:pfam09127  68 VGRMKFVRPLYRALNKVDRDLAVETFEKNKDFYHPICRAMVEKDL 112
Peptidase_M1_N pfam17900
Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from ...
70-245 9.41e-43

Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from the M1 family.


Pssm-ID: 465557 [Multi-domain]  Cd Length: 186  Bit Score: 152.50  E-value: 9.41e-43
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283     70 LHTDLNLSVSFEKSAISGSVTFQLKKlhegKNKSDELHLDTSYLDVQ------EVHIDGSKADFQIEQRKEPLgsrLVIN 143
Cdd:pfam17900   3 EHYDLDLKIDLKNFTFSGSVTITLQL----NNATNVIVLHASDLTIRsislsdEVTSDGVPADFTEDQKDGEK---LTIV 75
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283    144 NAS---CNDNFTLNIQFRT--TDKCTALQWLNSKQTKGGKPYVFSQLEAIHARSLFPCFDTPSVKSTFTASIESPLP-VV 217
Cdd:pfam17900  76 LPEtlnQTGPYTLEIEYSGelNDSMTGFYRSTYTDNGEKKVLVTTQFEPTDARSAFPCFDEPSVKATFTISIIHPKDyTA 155
                         170       180       190
                  ....*....|....*....|....*....|.
gi 6324283    218 FSGIRIEDTSKDTN---IYRFEQKVPIPAYL 245
Cdd:pfam17900 156 LSNMPVIASEPLENgwvITTFEQTPKMSTYL 186
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
68-496 6.08e-30

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 123.01  E-value: 6.08e-30
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283   68 AVLHTDLNLSVSFEKSAISGSVT--FQLKKlhegknKSDELHLDTSYLDVQEVHIDGSKADFQieqrkEPLGSRLVINNA 145
Cdd:cd09602  14 SVVSYDLDLDLTEGAETFRGTVTirFTLRE------PGASLFLDFRGGEVKSVTLNGRPLDPS-----AFDGERITLPGL 82
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  146 SCNDNFTLNIQFRTTDKCT--ALQWlnSKQTKGGKPYVFSQLEAIHARSLFPCFDTPSVKSTFTASIESPLP-VVFSGIR 222
Cdd:cd09602  83 LKAGENTVVVEFTAPYSSDgeGLHR--FVDPADGETYLYTLFEPDDARRVFPCFDQPDLKATFTLTVTAPADwTVISNGP 160
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  223 IEDTSK--DTNIYRFEQKVPIPAYLIGIASGDLSSApigpRSTVYTEPFRLkdcqweF--ENDVEKFIQTAEkiIFE--- 295
Cdd:cd09602 161 ETSTEEagGRKRWRFAETPPLSTYLFAFVAGPYHRV----EDEHDGIPLGL------YcrESLAEYERDADE--IFEvtk 228
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  296 -------------YEWGTYDiLVNVDSYPYGGMESPN--------MTFATPTliAHDRSN-IDVIAHELAHSWSGNLVTN 353
Cdd:cd09602 229 qgldfyedyfgipYPFGKYD-QVFVPEFNFGAMENPGavtfresyLFREEPT--RAQRLRrANTILHEMAHMWFGDLVTM 305
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  354 CSWNHFWLNEGWTVYLERRIIGAIHGEPT--RHFSALIGWSDLqnSIDSMKdperfST--LVQNLNDNTDPDDAFSTVPY 429
Cdd:cd09602 306 KWWDDLWLNESFADFMAAKALAEATPFTDawLTFLLRRKPWAY--RADQLP-----TThpIAQDVPDLEAAGSNFDGITY 378
                       410       420       430       440       450       460       470
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|.
gi 6324283  430 EKGFNLLFHLETILGgkaeFDPF---IRHYFKKFAKKSLDTFQFLDTLyefypEKKEILDSVDW-ETWLYK 496
Cdd:cd09602 379 AKGASVLKQLVALVG----EEAFragLREYFKKHAYGNATLDDLIAAL-----DEASGRDLSAWaDAWLRT 440
M1_APN_like cd09604
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains ...
282-474 1.15e-19

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains bacterial M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341067 [Multi-domain]  Cd Length: 440  Bit Score: 92.34  E-value: 1.15e-19
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  282 VEKFIQTAEKIIFEYEWGTYDIlvnVDSYPY-GGMESPNMTFATPTLIAHDRSNIDVIAHELAHSWSGNLVTNCSWNHFW 360
Cdd:cd09604 243 AKDALEFFSEKFGPYPYPELDV---VQGPFGgGGMEYPGLVFIGSRLYDPKRSLEGVVVHEIAHQWFYGIVGNDERREPW 319
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  361 LNEGWTVYLERRIIGAIHGEPTrhfsaliGWSDLQNSIDSMKDPERFSTLVQNLNDNTDPDDAFSTVpYEKGFNLLFHLE 440
Cdd:cd09604 320 LDEGLATYAESLYLEEKYGKEA-------ADELLGRRYYRAYARGPGGPINLPLDTFPDGSYYSNAV-YSKGALFLEELR 391
                       170       180       190
                ....*....|....*....|....*....|....
gi 6324283  441 TILgGKAEFDPFIRHYFKKFAKKSLDTFQFLDTL 474
Cdd:cd09604 392 EEL-GDEAFDKALREYYRRYKFKHPTPEDFFRTA 424
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
63-460 7.02e-18

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 86.80  E-value: 7.02e-18
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283   63 NYK--DFAVLHTDLNLSVSFEKSAISGSVTFQLKklhEGKNKSDELHLDTSYLDVQEVHIDG---SKADFQIEqrkeplG 137
Cdd:cd09600   1 DYKppDFLIDHVDLDFDLDDDETIVTSRLRVRRN---PDSGEGAPLVLDGEDLELLSVKIDGkplSPSDYTLD------E 71
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  138 SRLVINNAScnDNFTLNIQFRTT-DKCTALQWLnskqTKGGKPYVfSQLEAIHARSLFPCFDTPSVKSTFTASIESP--- 213
Cdd:cd09600  72 EGLTIKNVP--DRFVLEIEVRINpAANTSLEGL----YKSGGILC-TQCEAEGFRRITYFPDRPDVMSKFTVTIEADkek 144
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  214 LPVVFS-GIRIEDTSKDTNIY--RFEQKVPIPAYLIGIASGDLSSAP--IGPRS------TVYTEPFRLKDCQWEFEN-- 280
Cdd:cd09600 145 YPVLLSnGNLIEEGELPNGRHfaVWEDPFPKPSYLFALVAGDLGSVEdtFTTKSgrkvklRIYVEPGNEDKCHHAMESlk 224
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  281 -----DVEKFIqtaekiiFEYEWGTYDIlVNVDSYPYGGME--SPNmTFATPTLIAH-------DRSNI-DVIAHELAHS 345
Cdd:cd09600 225 kamkwDEERFG-------LEYDLDLFNI-VAVDDFNMGAMEnkGLN-IFNSKYVLADpetatdaDYERIeSVIAHEYFHN 295
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  346 WSGNLVTNCSWNHFWLNEGWTVYLERRiigaihgeptrhFSAligwsDLQNS----IDSmkdperfstlVQNLNDNTDPD 421
Cdd:cd09600 296 WTGNRVTCRDWFQLSLKEGLTVFRDQE------------FSA-----DMNSRavkrIED----------VRRLRSAQFPE 348
                       410       420       430       440       450
                ....*....|....*....|....*....|....*....|....*....|....*...
gi 6324283  422 DA-------------------FSTVpYEKGFNLLFHLETILGGKAeFDPFIRHYFKKF 460
Cdd:cd09600 349 DAgpmahpirpdsyieinnfyTVTV-YEKGAEVIRMLHTLLGEEG-FRKGMDLYFERH 404
GluZincin cd09594
Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, ...
295-373 1.47e-14

Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, M2, M3, M4, M13, M32 and M36 (fungalysins); The Gluzincin family (thermolysin-like peptidases or TLPs) includes several zinc-dependent metallopeptidases such as M1, M2, M3, M4, M13, M32, M36 peptidases (MEROPS classification), which contain the HEXXH motif as part of their active site. Peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. The M1 family includes aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity such that the two activities occupy different, but overlapping sites. The M3_like peptidases include the M2_ACE, M3 or neurolysin-like family (subfamilies M3B_PepF and M3A) and M32_Taq peptidases. The M2 peptidase angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II. ACE is a key component of the renin-angiotensin system that regulates blood pressure, thus ACE inhibitors are important for the treatment of hypertension. M3A includes thimet oligopeptidase (TOP; endopeptidase 3.4.24.15), neurolysin (3.4.24.16), and the mitochondrial intermediate peptidase; and M3B includes oligopeptidase F. The M32 family includes eukaryotic enzymes from protozoa Trypanosoma cruzi, a causative agent of Chagas' disease, and from Leishmania major, a parasite that causes leishmaniasis, making these enzymes attractive targets for drug development. The M4 family includes secreted protease thermolysin (EC 3.4.24.27), pseudolysin, aureolysin, and neutral protease as well as bacillolysin (EC 3.4.24.28) that degrade extracellular proteins and peptides for bacterial nutrition, especially prior to sporulation. Thermolysin is widely used as a nonspecific protease to obtain fragments for peptide sequencing as well as in production of the artificial sweetener aspartame. The M13 family includes neprilysin (EC 3.4.24.11) and endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), which fulfill a broad range of physiological roles due to the greater variation in the S2' subsite allowing substrate specificity and are prime therapeutic targets for selective inhibition. The peptidase M36 fungalysin family includes endopeptidases from pathogenic fungi. Fungalysin hydrolyzes extracellular matrix proteins such as elastin and keratin. Aspergillus fumigatus causes the pulmonary disease aspergillosis by invading the lungs of immuno-compromised animals and secreting fungalysin that possibly breaks down proteinaceous structural barriers.


Pssm-ID: 341057 [Multi-domain]  Cd Length: 105  Bit Score: 69.82  E-value: 1.47e-14
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  295 EYEWGTYDILV---NVDSYPYGGMESP-NMTFATPTLIAHDRSNIDVIAHELAHSWSGNLVTN-CSWNHFWLNEGWTVYL 369
Cdd:cd09594  22 YPVSPIYSLLVypaYVEVNAYNAMWIPsTNIFYGAGILDTLSGTIDVLAHELTHAFTGQFSNLmYSWSSGWLNEGISDYF 101

                ....
gi 6324283  370 ERRI 373
Cdd:cd09594 102 GGLV 105
M1_like_TAF2 cd09839
TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) ...
69-361 2.84e-05

TATA binding protein (TBP) associated factor 2; This family includes TATA binding protein (TBP) associated factor 2 (TAF2, TBP-associated factor TAFII150, transcription initiation factor TFIID subunit 2, RNA polymerase II TBP-associated factor subunit B), and has homology to the M1 gluzincin family. TAF2 is part of the TFIID multidomain subunit complex essential for transcription of most protein-encoded genes by RNA polymerase II. TAF2 is known to interact with the initiator element (Inr) found at the transcription start site of many genes, thus possibly playing a key role in promoter binding as well as start-site selection. Image analysis has shown TAF2 to form a complex with TAF1 and TBP, inferring its role in promoter recognition. Peptidases in the M1 family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. TAF2, however, lacks these active site residues.


Pssm-ID: 341074 [Multi-domain]  Cd Length: 531  Bit Score: 47.22  E-value: 2.84e-05
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283   69 VLHTDLNLSVSFEKSAISGSVTFQLKKLHegkNKSDELHLDTSYLDVQEVHIDGSKADFQIEQRKEPL------------ 136
Cdd:cd09839   1 VAHQKVELDVDFANRSIIGYTEITIVPTS---PDLRTIRLNCRQCKIKSVTVNGVEAEFTYNDPLQNLdlsdntdvnahh 77
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  137 ----------------GSRLVI-------------NNASCNDN-------------FTLNIQFRTTDKCTALQW-LNSKQ 173
Cdd:cd09839  78 elkrklaaalaepdegNEELVIslppsvkielqdpNSASTQATtsspdtsedeftpLTIRIEYSLKNPRDGLHFvGPDEG 157
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  174 TKGGKPYVF--SQLEAIHARSLFPCFDTPSVKSTFTASI-------------------------------ESPLPVVFSG 220
Cdd:cd09839 158 GDKRYPHVYttNSPLPGSARCWFPCVDSLWERCTWELEItvprtlgdagrpplagskededdddlteedkELEMVVVCSG 237
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  221 IRIE------DTSKdtNIYRFEQKVPIPAYLIGIASG-----DLSSAPI----------GPRSTVYTEPFRLKD----CQ 275
Cdd:cd09839 238 DLVEqvvhpeDPSK--KTFSFSLSNPTSAQHIGFAVGpfeivPLPEFREseeddklgssAVEVTGFCLPGRLEElrntCS 315
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  276 wefendvekFIQTAekiiFEY---EWGtydilvnvdSYPYG--------GMESPNMTFATPTLIA----HDRSNID---- 336
Cdd:cd09839 316 ---------FLHKA----MDFfeeEYG---------SYPFSsykqvfvdDLPEDVSSFASLSICSsrllYPPDIIDqaye 373
                       410       420
                ....*....|....*....|....*...
gi 6324283  337 ---VIAHELAHSWSGNLVTNCSWNHFWL 361
Cdd:cd09839 374 trrKLAHALASQWFGINIIPKTWSDTWL 401
COG3975 COG3975
Predicted metalloprotease, contains C-terminal PDZ domain [General function prediction only];
268-346 4.80e-04

Predicted metalloprotease, contains C-terminal PDZ domain [General function prediction only];


Pssm-ID: 443174 [Multi-domain]  Cd Length: 591  Bit Score: 43.27  E-value: 4.80e-04
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 6324283  268 PFRLK---DCQWEFE---NDVEKFIQTAEKIIFEYEWGTYDILVNVDSYPYGGME---SPNMTFATPTLIAHD--RSNID 336
Cdd:COG3975 200 PHRLAvwgDPNLDLErliADLKKIVEEQIALFGEAPYDRYLFLLHLTDDGYGGLEhrnSTALICPRDDLTDWDgyRRFLG 279
                        90
                ....*....|
gi 6324283  337 VIAHELAHSW 346
Cdd:COG3975 280 LLSHEYFHSW 289
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH